Preclinical Study Confirms Efficacy of Novel Cell Therapy Using iPS Cell-Derived NKT Cells — Potential to Strongly Elicit Patient-Specific Cancer-Reactive T Cells in Combination with Antigen-Presenting Cells —
NQ Score
88/100
N1 Content Completeness
90
AI Summary (NQ-processed)
A research group including Assistant Professor Takahiro Aoki, Professor Shinichiro Motohashi of Chiba University Graduate School of Medicine, and Team Director Akihiko Koseki of RIKEN Center for Integrative Medical Sciences, has clarified that strong anti-tumor effects can be obtained by combining iPS cell-derived "NKT cells" with "antigen-presenting cells presenting α-galactosylceramide." This combination therapy also increased cancer-reactive memory T cells in a mouse model transplanted with patient-derived lung cancer tissue and human immune cells, opening new avenues for personalized cell therapy.